Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Jump to: 2022 | 2021 | 2020 | 2018 | 2017 | 2011
Number of items: 10.

2022

Gluz, Oleg, Nitz, Ulrike, Kolberg-Liedtke, Cornelia, Prat, Aleix ORCID: 0000-0003-2377-540X, Christgen, Matthias, Kuemmel, Sherko, Mohammadian, Mohammad Parsa, Gebauer, Daniel, Kates, Ronald, Pare, Laia ORCID: 0000-0002-4904-558X, Grischke, Eva-Maria, Forstbauer, Helmut, Braun, Michael, Warm, Mathias, Hackmann, John, Uleer, Christoph, Aktas, Bahriye, Schumacher, Claudia, Wuerstlein, Rachel, Graeser, Monika, Pelz, Enrico, Jozwiak, Katarzyna ORCID: 0000-0002-9614-6586, Zu Eulenburg, Christine, Kreipe, Hans Heinrich and Harbeck, Nadia (2022). De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial. Clin. Cancer Res., 28 (22). S. 4995 - 5004. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1557-3265

Nitz, Ulrike, Gluz, Oleg, Graeser, Monika, Christgen, Matthias, Kuemmel, Sherko, Grischke, Eva-Maria, Braun, Michael, Augustin, Doris, Potenberg, Jochem, Krauss, Katja, Schumacher, Claudia, Forstbauer, Helmut, Reimer, Toralf, Stefek, Andrea, Fischer, Hans Holger, Pelz, Enrico, Zu Eulenburg, Christine, Kates, Ronald, Wuerstlein, Rachel, Kreipe, Hans Heinrich and Harbeck, Nadia (2022). De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol., 23 (5). S. 625 - 636. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

2021

Graeser, Monika ORCID: 0000-0003-1916-717X, Feuerhake, Friedrich, Gluz, Oleg, Volk, Valery, Hauptmann, Michael, Jozwiak, Katarzyna, Christgen, Matthias, Kuemmel, Sherko, Grischke, Eva-Maria, Forstbauer, Helmut, Braun, Michael, Warm, Mathias, Hackmann, John, Uleer, Christoph, Aktas, Bahriye, Schumacher, Claudia, Kolberg-Liedtke, Cornelia, Kates, Ronald, Wuerstlein, Rachel, Nitz, Ulrike, Kreipe, Hans Heinrich and Harbeck, Nadia (2021). Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial. J. Immunother. Cancer, 9 (5). LONDON: BMJ PUBLISHING GROUP. ISSN 2051-1426

Grote, Isabel ORCID: 0000-0002-6731-187X, Bartels, Stephan, Kandt, Leonie, Bollmann, Laura, Christgen, Henriette, Gronewold, Malte, Raap, Mieke, Lehmann, Ulrich, Gluz, Oleg, Nitz, Ulrike, Kuemmel, Sherko ORCID: 0000-0001-9355-494X, Zu Eulenburg, Christine, Braun, Michael, Aktas, Bahriye, Grischke, Eva-Maria, Schumacher, Claudia, Luedtke-Heckenkamp, Kerstin, Kates, Ronald, Wuerstlein, Rachel, Graeser, Monika, Harbeck, Nadia, Christgen, Matthias and Kreipe, Hans (2021). TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer. Cancer Med., 10 (23). S. 8581 - 8595. HOBOKEN: WILEY. ISSN 2045-7634

2020

Dowsett, Mitch, Ellis, Matthew J., Dixon, J. Michael, Gluz, Oleg, Robertson, John, Kates, Ronald, Suman, Vera J., Turnbull, Arran K., Nitz, Ulrike, Christgen, Matthias, Kreipe, Hans, Kuemmel, Sherko, Bliss, Judith M., Barry, Peter, Johnston, Stephen R., Jacobs, Samuel A., Ma, Cynthia X., Smith, Ian E. and Harbeck, Nadia (2020). Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic. npj Breast Cancer, 6 (1). LONDON: NATURE PUBLISHING GROUP. ISSN 2374-4677

Gluz, Oleg, Kolberg-Liedtke, Cornelia, Prat, Aleix ORCID: 0000-0003-2377-540X, Christgen, Matthias, Gebauer, Daniel, Kates, Ronald, Pare, Laia ORCID: 0000-0002-4904-558X, Grischke, Eva-Maria, Forstbauer, Helmut, Braun, Michael, Warm, Mathias, Hackmann, John, Uleer, Christoph, Aktas, Bahriye, Schumacher, Claudia, Kuemmel, Sherko, Wuerstlein, Rachel, Pelz, Enrico, Nitz, Ulrike, Kreipe, Hans Heinrich and Harbeck, Nadia (2020). Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial. Int. J. Cancer, 146 (1). S. 262 - 272. HOBOKEN: WILEY. ISSN 1097-0215

Griguolo, Gaia ORCID: 0000-0002-8782-4509, Braso-Maristany, Fara, Gonzalez-Farre, Blanca ORCID: 0000-0002-1796-7248, Pascual, Tomas ORCID: 0000-0001-8431-3183, Chic, Nuria, Sauri, Tamara, Kates, Ronald, Gluz, Oleg, Martinez, Debora, Pare, Laia ORCID: 0000-0002-4904-558X, Tsvetkova, Vassilena, Pesantez, David, Vidal, Maria, Adamo, Barbara, Munoz, Montserrat, Galvan, Patricia, Barbera, Laura, Cuatrecasas, Miriam, Christgen, Mathias, Kreipe, Hans, Monge-Escartin, Ines, Villagrasa, Patricia, Soy, Dolors, Giarratano, Tommaso, Dieci, Maria Vittoria, Conte, Pierfranco, Harbeck, Nadia, Guarneri, Valentina and Prat, Aleix (2020). ERBB2mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer. Cancers, 12 (7). BASEL: MDPI. ISSN 2072-6694

2018

Gluz, Oleg, Liedtke, Cornelia, Prat, Aleix, Christgen, Matthias, Gebauer, Daniel, Kates, Ronald, Pelz, Enrico, Clemens, Michael, Warm, Matthias, Aktas, Bahriye, Kuemmel, Sherko, Pare, Laia, Krabisch, Petra, Kreipe, Hans Heinrich, Wuerstlein, Rachel, Nitz, Ulrike and Harbeck, Nadia (2018). Genomic markers but not molecular subtypes provide prognostic impact and predict anthracycline efficacy in early triple-negative breast cancer: Results from the prospective WSG PlanB trial. Cancer Res., 78 (4). PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

2017

Harbeck, Nadia, Gluz, Oleg, Clemens, Michael R., Malter, Wolfram, Reimer, Toralf, Nuding, Benno, Aktas, Bahriye, Stefek, Andrea, Pollmanns, Anke, Lorenz-Salehi, Fatemeh, Uleer, Christoph, Krabisch, Petra, Kummel, Sherko, Liedtke, Cornelia, Shak, Steven, Wuerstlein, Rachel, Christgen, Matthias, Kates, Ronald, Kreipe, Hans Heinrich and Nitz, Ulrike (2017). Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC -> 4x doc vs. 6x docetaxel/cyclophospham ide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer. J. Clin. Oncol., 35. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

2011

Wuerstlein, Rachel, Liedtke, Cornelia, Gluz, Oleg, Heitz, Florian, Kates, Ronald, Fehm, Tanja, Nitz, Ulrike and Harbeck, Nadia (2011). PRIMARY TUMOR IN BREAST CANCER (BC) AND PHENOTYPE IN POSITIVE LYMPHNODES AND LATER DISEASE RECURRENCE (METASTATIC BREAST CANCER, MBC): RESULTS OF THE PRIMET-TRIAL (WSG/DETECT). Breast, 20. S. S22 - 2. EDINBURGH: CHURCHILL LIVINGSTONE. ISSN 0960-9776

This list was generated on Thu Mar 28 15:21:57 2024 CET.